Sanofi and Regeneron Report Positive Dupixent Data in Pediatric Eosinophilic Esophagitis

Intelligent Finance APP learned that Sanofi (SNY.US) and its partner Regeneron (REGN.US) released more positive data on Dupixent on Tuesday. The two companies stated that the new data shows that Dupixent has significant histological relief for eosinophilic esophagitis in children aged 1 to 11.

It is reported that eosinophilic esophagitis is a chronic immune system disease, which causes a type of white blood cell (eosinophil) to accumulate in the lining of the tube (esophagus) connecting the mouth and stomach, making it unable to function properly.